Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Pharmaceutical Insights: Disitamab Vedotin's R&D Progress and its Mechanism of Action on Drug Target
Drug Insights
4 min read
Pharmaceutical Insights: Disitamab Vedotin's R&D Progress and its Mechanism of Action on Drug Target
4 September 2023
This article summarized the latest R&D progress of Disitamab Vedotin, the Mechanism of Action for Disitamab Vedotin, and the drug target R&D trends for Disitamab Vedotin.
Read →
Comprehensive understanding of Proton Pump Inhibitors
Comprehensive understanding of Proton Pump Inhibitors
4 September 2023
Proton pumps are enzymes found in the stomach lining that play a crucial role in the production of gastric acid.
Read →
Overview of Exelixis’ Drug Pipeline | R&D Progress | Drug Target
R&D Pipeline
5 min read
Overview of Exelixis’ Drug Pipeline | R&D Progress | Drug Target
4 September 2023
Founded in 1994, Exelixis, Inc. is a biotechnology company in California focused on the anti-tumor field that has commercialized new drug products.
Read →
Genentech's Alecensa has achieved remarkable Phase III outcomes for individuals diagnosed with early-stage lung cancer that is positive for the ALK mutation
Latest Hotspot
6 min read
Genentech's Alecensa has achieved remarkable Phase III outcomes for individuals diagnosed with early-stage lung cancer that is positive for the ALK mutation
4 September 2023
Genentech announced today that the Phase III ALINA study assessing Alecensa® (alectinib) has achieved its primary endpoint of disease-free survival (DFS) during a pre-determined interim analysis.
Read →
Exploring Brotizolam's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
Drug Insights
4 min read
Exploring Brotizolam's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
4 September 2023
Brotizolam is a small molecule drug that targets the GABAA receptor in the nervous system.
Read →
Unveiling the Veil of JAK Inhibitors
Unveiling the Veil of JAK Inhibitors
4 September 2023
JAK inhibitors can inhibit JAK kinases, block the JAK-STAT signaling pathway, and have great therapeutic potential for a variety of diseases including tumors, immune & inflammation···
Read →
Analysis of Amgen’s Drug Development Pipeline | R&D Progress | Drug Target
R&D Pipeline
4 min read
Analysis of Amgen’s Drug Development Pipeline | R&D Progress | Drug Target
4 September 2023
Amgen Inc. is a biotechnology company dedicated to providing biological therapeutics to patients with serious diseases by discovering, developing, manufacturing, and delivering innovative human therapies.
Read →
The U.S. has granted IND approval to HBM9033, the initial ADC project for solid tumors by Harbour BioMed
Latest Hotspot
4 min read
The U.S. has granted IND approval to HBM9033, the initial ADC project for solid tumors by Harbour BioMed
4 September 2023
Harbour BioMed declared that the U.S. FDA has given the go-ahead for the IND application, permitting the initiation of clinical studies for its inaugural Antibody Drug Conjugate (ADC) project, HBM9033.
Read →
Decoding Bromocriptine Mesylate: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
Drug Insights
5 min read
Decoding Bromocriptine Mesylate: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
4 September 2023
This article summarized the latest R&D progress of Bromocriptine Mesylate, the Mechanism of Action for Bromocriptine Mesylate, and the drug target R&D trends for Bromocriptine Mesylate.
Read →
MAO Inhibitors -the Redemption of Depression
MAO Inhibitors -the Redemption of Depression
4 September 2023
Monoamine Oxidase(MAO) is a naturally existing oxidase in the human body, located on the outer membrane of mitochondria.
Read →
Review of Alkermes Plc’s Drug Pipeline | R&D Status | Therapeutic Areas
R&D Pipeline
5 min read
Review of Alkermes Plc’s Drug Pipeline | R&D Status | Therapeutic Areas
4 September 2023
Alkermes Plc is a biopharmaceutical company focused on central nervous system (CNS) disorders such as schizophrenia, depression, addiction, and multiple sclerosis.
Read →
The FDA has given its approval to Mallinckrodt for marketing Dextroamphetamine for managing Attention Deficit/Hyperactivity Disorder (ADHD)
Latest Hotspot
4 min read
The FDA has given its approval to Mallinckrodt for marketing Dextroamphetamine for managing Attention Deficit/Hyperactivity Disorder (ADHD)
4 September 2023
The FDA has given Mallinckrodt the green light to market Lisdexamfetamine Dimesylate Capsules, a product intended to mitigate Attention-Deficit/Hyperactivity Disorder (ADHD).
Read →